Abstract:The purpose of this study was to develop Bi-parametric Magnetic Resonance Imaging (BP-MRI) based radiomics models for differentiation between benign and malignant prostate lesions, and to cross-vendor validate the generalization ability of the models. The prebiopsy BP-MRI data (T2-Weighted Image [T2WI] and the Apparent Diffusion Coefficient [ADC]) of 459 patients with clinical suspicion of prostate cancer were acquired using two scanners from different vendors. The prostate biopsies are the reference standard for diagnosing benign and malignant prostate lesions. The training set was 168 patients' data from Siemens (Vendor 1), and the inner test set was 70 patients' data from the same vendor. The external test set was 221 patients' data from GE (Vendor 2). The lesion Region of Interest (ROI) was manually delineated by experienced radiologists. A total of 851 radiomics features including shape, first-order statistical, texture, and wavelet features were extracted from ROI in T2WI and ADC, respectively. Two feature-ranking methods (Minimum Redundancy Maximum Relevance [MRMR] and Wilcoxon Rank-Sum Test [WRST]) and three classifiers (Random Forest [RF], Support Vector Machine [SVM], and the Least Absolute Shrinkage and Selection Operator [LASSO] regression) were investigated for their efficacy in building single-parametric radiomics signatures. A biparametric radiomics model was built by combining the optimal single-parametric radiomics signatures. A comprehensive diagnosis model was built by combining the biparametric radiomics model with age and Prostate Specific Antigen (PSA) value using multivariable logistic regression. All models were built in the training set and independently validated in the inner and external test sets, and the performances of models in the diagnosis of benign and malignant prostate lesions were quantified by the Area Under the Receiver Operating Characteristic Curve (AUC). The mean AUCs of the inner and external test sets were calculated for each model. The non-inferiority test was used to test if the AUC of model in external test was not inferior to the AUC of model in inner test. Combining MRMR and LASSO produced the best-performing single-parametric radiomics signatures with the highest mean AUC of 0.673 for T2WI (inner test AUC = 0.729 vs. external test AUC = 0.616, p = 0.569) and the highest mean AUC of 0.810 for ADC (inner test AUC = 0.822 vs. external test AUC = 0.797, p = 0.102). The biparametric radiomics model produced a mean AUC of 0.833 (inner test AUC = 0.867 vs. external test AUC = 0.798, p = 0.051). The comprehensive diagnosis model had an improved mean AUC of 0.911 (inner test AUC = 0.935 vs. external test AUC = 0.886, p = 0.010). The comprehensive diagnosis model for differentiating benign from malignant prostate lesions was accurate and generalizable.

Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL

The Potential of a Nomogram Combined PI-RADS V2.1 and Contrast-Enhanced Ultrasound (CEUS) to Reduce Unnecessary Biopsies in Prostate Cancer Diagnostics

Utility of Clinical-Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions

Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram

Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions

Magnetic resonance imaging radiomics-based prediction of clinically significant prostate cancer in equivocal PI-RADS 3 lesions in the transitional zone

Predicting prostate cancer in men with PSA levels of 4–10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance

A Nomogram Based on a Multiparametric Ultrasound Radiomics Model for Discrimination Between Malignant and Benign Prostate Lesions

MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies

Comparison in prostate cancer diagnosis with PSA 4-10 ng/mL: radiomics-based model VS. PI-RADS v2.1

Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature

Diagnostic nomogram based on intralesional and perilesional radiomics features and clinical factors of clinically significant prostate cancer

Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making

Multi-parametric MRI-based Radiomics Signature for Discriminating Between Clinically Significant and Insignificant Prostate Cancer: Cross-validation of a Machine Learning Method.

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI

Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer

A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml

Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions

Radiomics from multisite MRI and clinical data to predict clinically significant prostate cancer

Multi-view radiomics and deep learning modeling for prostate cancer detection based on multi-parametric MRI

Bi-parametric magnetic resonance imaging based radiomics for the identification of benign and malignant prostate lesions: cross-vendor validation